Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-income and middle-income countries: a modeling study

This modeling study projects that bivalent HPV vaccination in 117 low- and middle-income countries could prevent approximately 4.8 million non-cervical cancer cases and 3 million deaths among women by 2100, with the greatest relative benefits expected in the African Region, thereby strengthening the public health case for expanding vaccine access and addressing global health disparities.

The Gist

Imagine the human body as a vast, bustling city. In this city, there are tiny, invisible saboteurs called Human Papillomavirus (HPV). While most people know these saboteurs for attacking the "Cervical District" (the cervix), they are actually master thieves who can break into other parts of the city too, causing trouble in the "Anal Alley," "Oropharyngeal Plaza," "Vaginal Valley," and "Vulvar Village."

For a long time, the city's defense plan (vaccination) focused almost entirely on protecting the Cervical District. This paper is like a new, expanded blueprint that asks: "What if we also protect the other neighborhoods?"

Here is the story of that blueprint, broken down simply:

1. The Mission: Looking Beyond the Main Target

The researchers (a team of global health detectives) decided to run a simulation. They wanted to see what would happen if we vaccinated young girls in 117 poorer countries (Low- and Middle-Income Countries) against HPV.

Instead of just counting how many cervical cancers we stop, they asked: "How many other cancers will we prevent?" They looked at four other types of cancer caused by the same virus: anal, throat (oropharyngeal), vaginal, and vulvar.

2. The Simulation: A Time-Traveling Crystal Ball

The team used a computer model—a kind of "crystal ball"—to project the future from 2030 all the way to the year 2100.

Think of this model as a giant garden.

• Without the vaccine: The garden is overrun by weeds (cancer) in all these different districts.
• With the vaccine: We plant a special shield (the bivalent HPV vaccine) that stops the specific weeds (HPV types 16 and 18) from ever taking root.

The model calculated how many weeds would be pulled out of the ground over the next 70 years if we kept planting this shield.

3. The Big Reveal: A Massive Harvest Saved

The results were staggering. By protecting the girls in these 117 countries, the world could prevent:

• 590,000 cases of anal cancer.
• 880,000 cases of throat cancer.
• 1.27 million cases of vaginal cancer.
• 2.18 million cases of vulvar cancer.

In total, this is like saving 3 million lives from these specific cancers by the end of the century. That's a whole city's population of people who get to live long, healthy lives instead of dying from cancer.

4. The Geography: Where the Shield Works Best

The study found that the "shield" doesn't work the same way everywhere. It's like putting a raincoat on different people in different weather:

• The African Region (AFR): This is where the rain is heaviest (highest cancer rates) and where people have the least raincoats. Here, the vaccine is a superhero. It's projected to stop the most cancer cases and deaths relative to the problem size. It's like putting a fire extinguisher in a house that's already on fire—it saves the most lives.
• The European Region (EUR): This area already has better defenses and lower fire risks. The vaccine still helps, but the relative improvement looks smaller because the starting point was safer.
• The "Top 10" Heroes: Countries like India, Nigeria, and Ethiopia are projected to save the most lives simply because they have the largest populations and the highest current risks.

5. The Catch: Not All Cancers Are Stopped Equally

The vaccine is a master key for some doors but less effective for others:

• Vulvar and Anal Cancers: The vaccine is incredibly good at stopping these. By 2100, nearly 60 countries will have cut deaths from anal cancer by at least 25%.
• Throat (Oropharyngeal) Cancer: This is the hardest door to lock. Only about 25 countries are projected to see a 25% drop in deaths. Why? Because the virus behaves differently in the throat, and the data is trickier to predict.

6. Why This Matters: The "Double-Dip" Benefit

The authors argue that we need to change the conversation.

• Old Story: "We need HPV vaccines to stop cervical cancer."
• New Story: "We need HPV vaccines to stop cervical cancer AND anal, throat, vaginal, and vulvar cancers."

Think of it like buying a security system for your house. You might buy it to stop burglars from the front door (cervix), but you discover it also stops them from breaking in through the back door, the window, and the basement. You get way more value for your money.

The Bottom Line

This paper is a wake-up call for policymakers and health organizations. It says: "Don't just look at the main target. Look at the whole picture."

By recognizing that the HPV vaccine protects women from multiple types of cancer, not just one, we can:

1. Justify spending more money on vaccines in poor countries.
2. Design better programs that reach the people who need them most (especially in Africa and Asia).
3. Save millions more lives than we thought possible.

In short, the HPV vaccine is a "Swiss Army Knife" of public health. This study shows us just how many different tools are inside that knife, and how much good they can do if we just hand them out to the right people.

Technical Summary

1. Problem Statement

While Human Papillomavirus (HPV) vaccination programs have historically focused on preventing cervical cancer, HPV is also the primary etiological agent for several other malignancies, including anal, oropharyngeal, vaginal, and vulvar cancers.

• The Gap: Most health impact assessments in Low- and Middle-Income Countries (LMICs) have quantified the benefits of vaccination solely regarding cervical cancer. The broader public health impact of preventing non-cervical HPV-attributable cancers in these resource-limited settings remains underexplored.
• The Need: There is a critical need to estimate the full spectrum of cancer prevention benefits to strengthen the economic and policy case for scaling up HPV vaccination, particularly in regions with high disease burdens and limited access to care.

2. Methodology

The study employed a static cohort model to project the health impact of bivalent HPV vaccination (targeting HPV types 16 and 18) among female cohorts in 117 LMICs over a 70-year horizon (2030–2100).

• Model Framework:
  • The model compares two scenarios: "No Vaccination" vs. "Vaccination."
  • It utilizes a simplified decision-tree approach rather than a full dynamic transmission model. It estimates the proportional reduction in non-cervical cancer burden based on vaccine efficacy, coverage, and HPV type distribution.
  • Cohort: Female cohorts vaccinated at age 9 (or the age of introduction) and followed throughout their lifetimes.
• Key Inputs:
  • Demographics: Age-specific population projections (UN World Population Prospects 2019) and life expectancy (WHO 2019 life tables).
  • Epidemiology: Age-specific cancer incidence rates for anal, oropharyngeal, vaginal, and vulvar cancers sourced from GLOBOCAN (IARC/WHO). For countries lacking data, regional and income-category averages were applied.
  • HPV Type Distribution: Relative contributions of HPV 16/18 to non-cervical cancers were based on de Sanjosé et al. (2019) and other regional studies. Assumptions were made for missing data (e.g., using regional proxies for the African Region).
  • Vaccination Parameters:
    • Efficacy: Assumed lifelong 100% efficacy against HPV 16/18 infections.
    • Coverage: Historical data (WHO/UNICEF WUENIC) up to 2022; projected growth of 1 percentage point annually from 2023–2100, capped at 95%.
  • Mortality: Cause-specific probability of death derived from the HPV Stats database, adjusted for cancer stage distributions.
• Uncertainty Analysis:
  • Probabilistic Sensitivity Analysis (PSA) was conducted using 200 independent parameter sets.
  • Key parameters (HPV type distribution, incidence rates, probability of death) were assigned beta-PERT distributions to generate 95% uncertainty intervals (UIs).

3. Key Contributions

• Scope Expansion: This is one of the first comprehensive modeling studies to quantify the impact of HPV vaccination specifically on non-cervical cancers (anal, oropharyngeal, vaginal, vulvar) across 117 LMICs.
• Regional Granularity: The study provides granular projections across six WHO regions (AFR, AMR, EMR, EUR, SEAR, WPR), highlighting significant disparities in potential health gains.
• Long-term Horizon: The analysis extends to the year 2100, capturing the long-term cumulative benefits of vaccination programs.
• Policy Relevance: It offers evidence to support the inclusion of non-cervical cancer outcomes in cost-effectiveness analyses and funding decisions (e.g., by Gavi, the Vaccine Alliance).

4. Key Results

The study projects substantial reductions in both cancer cases and deaths over the 2030–2100 period:

• Total Cases Averted (117 LMICs):

  • Anal Cancer: ~590,000 cases (95% UI: 560k–630k)
  • Oropharyngeal Cancer: ~880,000 cases (95% UI: 820k–950k)
  • Vaginal Cancer: ~1.27 million cases (95% UI: 1.20m–1.35m)
  • Vulvar Cancer: ~2.18 million cases (95% UI: 2.09m–2.29m)
  • Total: ~4.92 million non-cervical cancer cases averted.

• Total Deaths Averted:

  • 3.02 million deaths (95% UI: 2.85m–3.20m) from non-cervical cancers are projected to be averted by 2100.
  • Breakdown: 360k (Anal), 550k (Oropharyngeal), 800k (Vaginal), 1.30m (Vulvar).

• Regional Disparities:

  • African Region (AFR): Expected to see the largest relative reductions. For example, AFR accounts for 330,000 averted anal cancer cases and 1.07 million averted vulvar cancer cases. The region showed the highest percentage reduction in deaths for vulvar cancer (44.7%).
  • Western Pacific (WPR) & European (EUR): Showed the smallest relative gains due to lower baseline burdens or different epidemiological contexts.
  • Mortality Reduction Thresholds: By 2100, 58 countries are projected to achieve at least a 25% reduction in anal cancer deaths, compared to only 25 countries for oropharyngeal cancer.

• Cancer Type Variability:

  • Vulvar cancer showed the greatest reduction in deaths across most regions.
  • Oropharyngeal cancer showed the slowest progress in reaching the 25% mortality reduction threshold (only 25 countries).

5. Significance and Implications

• Public Health Justification: The findings demonstrate that HPV vaccination offers a "multi-cancer" benefit, preventing nearly 5 million cases and 3 million deaths from non-cervical cancers in LMICs alone. This significantly strengthens the argument for vaccination as a high-value intervention.
• Equity and Resource Allocation: The disproportionate impact in the African Region highlights the urgent need for targeted scale-up in high-burden, low-coverage settings. It suggests that current vaccination efforts are preventing a massive future burden of disease that is currently overlooked.
• Policy Recommendations:
  • Beyond Cervical Focus: Policymakers and funders (e.g., Gavi) should incorporate non-cervical cancer outcomes into health economic models to better reflect the true value of the vaccine.
  • Tailored Strategies: A "one-size-fits-all" approach is insufficient. Strategies must be region-specific, potentially including catch-up campaigns for older adolescents and integrating vaccination into existing health platforms (e.g., antenatal care) to improve coverage.
  • Data Gaps: The study underscores the critical need for better local data on non-cervical cancer incidence and HPV type distribution in LMICs to refine future models.

Limitations: The study used a static model (ignoring herd immunity, though noting that high coverage in girls minimizes this difference) and relied on extrapolated data for countries lacking GLOBOCAN estimates. However, the authors argue these findings serve as robust qualitative indicators of the magnitude and distribution of health impacts.